Research map: Effect of Hepatic Impairment on the Pharmacokinetics of Single-Dose Viloxazine Extended-Release Capsules (Qelbree®) in Adults

Back to the article

Papers in this map

  1. Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction · Roger Karel Verbeeck · 2008 · 655 citations · Cited by this paper
  2. Effectiveness and Tolerability of Vortioxetine in Major Depressive Disorder: A Real-World Study in Switzerland · 2026 · Related
  3. Clinical Pharmacokinetic and Pharmacodynamic Considerations in Patients with Liver Disease · Denis J. Morgan · 1995 · 210 citations · Cited by this paper
  4. Clinical Benefit of Multiple Myeloma Drugs at Regulatory Approval in Brazil, Europe, and the USA: A Retrospective Cohort Study (2003–2024) · 2026 · Related
  5. Renal dysfunction in chronic liver disease · Andy Slack · 2010 · 120 citations · Cited by this paper
  6. Desvenlafaxine as a Potential First-Line Treatment for Major Depressive Disorder: A Comprehensive Review and Consensus-Based Clinical Perspective on Efficacy, Safety and Patient Selection Profiles · 2026 · Related
  7. New Insights into the Mechanism of Action of Viloxazine: Serotonin and Norepinephrine Modulating Properties · Chung‐Ping Yu · 2020 · 93 citations · Cited by this paper
  8. Determinants and Prognostic Impact of In-Hospital Sodium-Glucose Cotransporter-2 Inhibitor Initiation in Patients with Heart Failure · 2026 · Related
  9. Viloxazine · R. M. Pinder · 1977 · 86 citations · Cited by this paper
  10. Missed Opportunities in the Therapeutic Patterns of Chronic Obstructive Pulmonary Disease: A Real-World Italian Study on the Impact of Severe Exacerbation on Mortality and Hospital Re-admission · 2026 · Related
  11. A Phase III, Randomized, Placebo-controlled Trial to Assess the Efficacy and Safety of Once-daily SPN-812 (Viloxazine Extended-release) in the Treatment of Attention-deficit/Hyperactivity Disorder in School-age Children · Azmi F. Nasser · 2020 · 85 citations · Cited by this paper
  12. Milsaperidone: First Approval · 2026 · Related
  13. A Phase II Double-Blind, Placebo-Controlled, Efficacy and Safety Study of SPN-812 (Extended-Release Viloxazine) in Children With ADHD · Janet K. Johnson · 2019 · 62 citations · Cited by this paper
  14. Cost-Consequences Analysis of Biologic Treatments for Moderate-to-Severe Crohn’s Disease Using Real-World Transition Probability and Cost Data in Thailand · 2026 · Related
  15. Once-Daily SPN-812 200 and 400 mg in the treatment of ADHD in School-aged Children: A Phase III Randomized, Controlled Trial · Azmi F. Nasser · 2021 · 55 citations · Cited by this paper
  16. Amyloid-Related Imaging Abnormalities in Anti-amyloid Therapy: Clinical Implications of Kinetics for Safer Use and Risk Stratification · 2026 · Related
  17. Effects of viloxazine, its optical isomers and its major metabolites on biogenic amine uptake mechanisms in vitro and in vivo · Thomas P. Blackburn · 1978 · 42 citations · Cited by this paper
  18. Over-the-Counter Product Use Among Individuals with Vitiligo: A Cross-Sectional International Survey · 2026 · Related
  19. Pharmacokinetics of Coadministered Viloxazine Extended-Release (SPN-812) and Lisdexamfetamine in Healthy Adults · Shamia L. Faison · 2021 · 28 citations · Cited by this paper
  20. Safety, Tolerability, and Pharmacokinetics of Subcutaneous Extended-Release Injectable Olanzapine in Patients with Schizophrenia and Schizoaffective Disorder · 2026 · Related
  21. Metabolism and in vitro drug–drug interaction assessment of viloxazine · Chung‐Ping Yu · 2020 · 26 citations · Cited by this paper
  22. Blood level studies with viloxazine hydrochloride in man. · P. F. C. Bayliss · 1975 · 24 citations · Cited by this paper
  23. Pharmacokinetics of Coadministered Viloxazine Extended-Release (SPN-812) and Methylphenidate in Healthy Adults · Shamia L. Faison · 2020 · 23 citations · Cited by this paper
  24. The effect of viloxazine hydrochloride on the transport of noradrenaline, dopamine, 5-hydroxytryptamine and γ-amino-butyric acid in rat brain tissue · Ian L. Martin · 1978 · 22 citations · Cited by this paper
  25. Evaluation of the Effect of SPN-812 (Viloxazine Extended-Release) on QTc Interval in Healthy Adults · Azmi F. Nasser · 2020 · 19 citations · Cited by this paper
  26. Impact of Paroxetine, a Strong CYP2D6 Inhibitor, on SPN‐812 (Viloxazine Extended‐Release) Pharmacokinetics in Healthy Adults · Zhao Wang · 2021 · 16 citations · Cited by this paper
  27. Viloxazine Increases Extracellular Concentrations of Norepinephrine, Dopamine, and Serotonin in the Rat Prefrontal Cortex at Doses Relevant for the Treatment of Attention-Deficit/Hyperactivity Disorder · Jennie García‐Olivares · 2024 · 12 citations · Cited by this paper
  28. Impact of Viloxazine Extended-Release Capsules (Qelbree®) on Select Cytochrome P450 Enzyme Activity and Evaluation of CYP2D6 Genetic Polymorphisms on Viloxazine Pharmacokinetics · Zhao Wang · 2024 · 5 citations · Cited by this paper
  29. Untitled · Cited by this paper

Source: OpenAlex (CC0)